Welcome!

News Feed Item

Boston Therapeutics Reports Third Quarter and Nine Months 2012 Financial Results

MANCHESTER, NH -- (Marketwire) -- 11/14/12 -- Boston Therapeutics, Inc. (OTCQB: BTHE)

  • SUGARDOWN® sales increased approximately 700% in the first nine months of 2012 compared with the same period in 2011
  • Completed PAZ320 Phase II clinical trial at Dartmouth Medical Center: Results expected to be published in peer-reviewed journal
  • FDA approves Boston Therapeutics petition to File an ANDA for BTI-7 to treat diabetes
  • Jonathan B. Rome, former CEO of ThePharmaNetwork, was recently named Chief Operating Officer to accelerate commercialization of SUGARDOWN® and to file an ANDA for BTI-7

Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, today announced financial results for the three and nine months ended September 30, 2012. These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with the SEC.

"We made good progress this year laying the foundation to commercialize our complex carbohydrate diabetes compounds," said David Platt, Ph.D., Chairman and Chief Executive Officer of Boston Therapeutics. "The recent addition of Jonathan Rome as our Chief Operating Officer will help accelerate the commercialization of SUGARDOWN® and the filing of an Abbreviated New Drug Application for BTI-7, a new, chewable dosage form of the diabetes drug metformin hydrochloride. We believe 2013 could be an exciting year for our Company as we ramp up operations."

Financial Results for the Three and Nine Months ended September 30, 2012
Revenue for the three and nine month periods ended September 30, 2012 increased to $2,520 and $23,750, respectively, compared with $724 and $2,971, respectively, for the same periods in the prior year. Revenues for both periods were generated from the sale of SUGARDOWN® while the increase was primarily attributable to distribution through a new reseller, especially in the first quarter of 2012.

Cost of goods sold for the three and nine months ended September 30, 2012 were $9,120 and $40,877, respectively, compared to $2,834 and $5,084, respectively, for the same periods in the prior year, an increase of $6,286 and $35,793, respectively. Cost of goods sold consisted primarily of the cost of the materials and labor to manufacture SUGARDOWN®, shipping and fulfillment costs. The Company's negative gross profit is attributable to cost of goods sold outpacing sales as a result of additional fixed costs related to moving to a new fulfillment operation, and manufacturing scale-up from small to production grade equipment.

Research and development expense for the three and nine month periods ended September 30, 2012 were $26,116 and $145,668, respectively, compared with $94,222 and $127,433, respectively, for the same periods in the prior year. Research and development expenses for the three months ended September 30, 2012 consisted of $16,000 in amortization of intellectual property and $10,000 in direct costs associated with the development of PAZ320. Research and development costs for the same period in 2011 consisted of $16,000 in amortization of intellectual property and $78,000 in direct costs associated with the development of SUGARDOWN®. Research and development expenses for the nine month period ended September 30, 2012 consisted of $48,000 in amortization of intellectual property and $98,000 in direct costs associated with the development or PAZ320. Research and development expenses for the nine month period ended September 30, 2011 consisted of $48,000 in amortization of intellectual property and $79,000 in costs associated with the development of SUGARDOWN®.

Sales and marketing expenses were $93,519 and $227,597 for the three and nine month periods ended September 30, 2012, respectively, compared with $132,842 and $134,839, respectively, for the same periods in the prior year. The 2012 amounts represent costs incurred for investor relations and other marketing and promotion activities. The 2011 amounts are primarily related to stock based compensation.

General and administrative expense for the three and nine month periods ended September 30, 2012 were $234,632 and $498,603, respectively, compared with $115,208 and $265,503, respectively, for the same periods in the prior year, an increase of $119,424 and $233,100, respectively. The 2012 increases consist primarily of consulting expenses of $94,000 and $114,000 for the three and nine month periods, respectively.

The Company had a net loss of $366,334, or ($0.02) per share, for the three months ended September 30, 2012 and a net loss of $905,728, or ($0.05) per share, for the nine months ended September 30, 2012, compared with a net loss of $348,606 or ($0.02) and $541,322 or ($0.04), respectively, for the same periods in the prior year. The Company's cash balance at September 30, 2012 was $169,321. The weighted average diluted shares outstanding for the three and nine month periods ended September 30, 2012 were 17,348,206 and 16,619,598, respectively.

About Boston Therapeutics, Inc.
Boston Therapeutics, headquartered in Manchester, NH, (OTCQB: BTHE) is a leader in the field of complex carbohydrates. The Company's initial product pipeline is focused on developing and commercializing therapeutic molecules for diabetes: SUGARDOWN®, a non-systemic chewable complex carbohydrate dietary supplement tablet designed to moderate post-meal blood glucose; BTI-7, a new, chewable dosage form of the diabetes drug metformin hydrochloride; PAZ320, a non-systemic chewable therapeutic compound designed to reduce post-meal glucose elevation, and IPOXYN™, an injectable anti-necrosis drug specifically designed to treat lower limb ischemia associated with diabetes. More information is available at www.bostonti.com and www.sugardown.com.

Forward-Looking Statements
The Company's views as of the date of this press release should not be relied upon to represent the Company's views as of a subsequent date. While the Company anticipates that subsequent events may cause the Company's views to change, the Company disclaims any obligation to update such forward-looking statements. This press release contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as "may," "estimate," "could," "expect" and others. They are based on our current expectations and are subject to factors and uncertainties which could cause actual results to differ materially from those described in the statements. Factors that could cause our actual performance to differ materially from those discussed in the forward-looking statements include, among others: incurrence of operating losses since our inception, uncertainty as to adequate financing of our operations, extensive and costly regulatory oversight that could restrict or prevent product commercialization, inability to achieve commercial product acceptance, inability to protect our intellectual property, dependence on strategic partnerships, product competition, and others stated in risk factors contained in our SEC filings. We cannot assure that we have identified all risks or that others may emerge which we do not anticipate. More information about those risks and uncertainties is contained and discussed in the Company's most recent quarterly or annual report and in the Company's other reports filed with the Securities and Exchange Commission.

Contact:
Boston Therapeutics, Inc.
Anthony Squeglia
Phone: 603-935-9799
Email [email protected]
www.bostonti.com

Investor Relations:
MZ Group
Scott Powell
Senior Vice President
Phone: 212-301-7130
Email: [email protected]
Web: www.mz-ir.com

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
The best way to leverage your CloudEXPO | DXWorldEXPO presence as a sponsor and exhibitor is to plan your news announcements around our events. The press covering CloudEXPO | DXWorldEXPO will have access to these releases and will amplify your news announcements. More than two dozen Cloud companies either set deals at our shows or have announced their mergers and acquisitions at CloudEXPO. Product announcements during our show provide your company with the most reach through our targeted audienc...
With 10 simultaneous tracks, keynotes, general sessions and targeted breakout classes, @CloudEXPO and DXWorldEXPO are two of the most important technology events of the year. Since its launch over eight years ago, @CloudEXPO and DXWorldEXPO have presented a rock star faculty as well as showcased hundreds of sponsors and exhibitors!
In an era of historic innovation fueled by unprecedented access to data and technology, the low cost and risk of entering new markets has leveled the playing field for business. Today, any ambitious innovator can easily introduce a new application or product that can reinvent business models and transform the client experience. In their Day 2 Keynote at 19th Cloud Expo, Mercer Rowe, IBM Vice President of Strategic Alliances, and Raejeanne Skillern, Intel Vice President of Data Center Group and ...
In his Opening Keynote at 21st Cloud Expo, John Considine, General Manager of IBM Cloud Infrastructure, led attendees through the exciting evolution of the cloud. He looked at this major disruption from the perspective of technology, business models, and what this means for enterprises of all sizes. John Considine is General Manager of Cloud Infrastructure Services at IBM. In that role he is responsible for leading IBM’s public cloud infrastructure including strategy, development, and offering m...
More and more brands have jumped on the IoT bandwagon. We have an excess of wearables – activity trackers, smartwatches, smart glasses and sneakers, and more that track seemingly endless datapoints. However, most consumers have no idea what “IoT” means. Creating more wearables that track data shouldn't be the aim of brands; delivering meaningful, tangible relevance to their users should be. We're in a period in which the IoT pendulum is still swinging. Initially, it swung toward "smart for smart...
DXWorldEXPO LLC announced today that All in Mobile, a mobile app development company from Poland, will exhibit at the 22nd International CloudEXPO | DXWorldEXPO. All In Mobile is a mobile app development company from Poland. Since 2014, they maintain passion for developing mobile applications for enterprises and startups worldwide.
@DevOpsSummit at Cloud Expo, taking place November 12-13 in New York City, NY, is co-located with 22nd international CloudEXPO | first international DXWorldEXPO and will feature technical sessions from a rock star conference faculty and the leading industry players in the world.
In his keynote at 19th Cloud Expo, Sheng Liang, co-founder and CEO of Rancher Labs, discussed the technological advances and new business opportunities created by the rapid adoption of containers. With the success of Amazon Web Services (AWS) and various open source technologies used to build private clouds, cloud computing has become an essential component of IT strategy. However, users continue to face challenges in implementing clouds, as older technologies evolve and newer ones like Docker c...
All organizations that did not originate this moment have a pre-existing culture as well as legacy technology and processes that can be more or less amenable to DevOps implementation. That organizational culture is influenced by the personalities and management styles of Executive Management, the wider culture in which the organization is situated, and the personalities of key team members at all levels of the organization. This culture and entrenched interests usually throw a wrench in the work...
We all know that end users experience the internet primarily with mobile devices. From an app development perspective, we know that successfully responding to the needs of mobile customers depends on rapid DevOps – failing fast, in short, until the right solution evolves in your customers' relationship to your business. Whether you’re decomposing an SOA monolith, or developing a new application cloud natively, it’s not a question of using microservices - not doing so will be a path to eventual ...
The next XaaS is CICDaaS. Why? Because CICD saves developers a huge amount of time. CD is an especially great option for projects that require multiple and frequent contributions to be integrated. But… securing CICD best practices is an emerging, essential, yet little understood practice for DevOps teams and their Cloud Service Providers. The only way to get CICD to work in a highly secure environment takes collaboration, patience and persistence. Building CICD in the cloud requires rigorous ar...
DXWorldEXPO LLC announced today that ICC-USA, a computer systems integrator and server manufacturing company focused on developing products and product appliances, will exhibit at the 22nd International CloudEXPO | DXWorldEXPO. DXWordEXPO New York 2018, colocated with CloudEXPO New York 2018 will be held November 11-13, 2018, in New York City. ICC is a computer systems integrator and server manufacturing company focused on developing products and product appliances to meet a wide range of ...
Coca-Cola’s Google powered digital signage system lays the groundwork for a more valuable connection between Coke and its customers. Digital signs pair software with high-resolution displays so that a message can be changed instantly based on what the operator wants to communicate or sell. In their Day 3 Keynote at 21st Cloud Expo, Greg Chambers, Global Group Director, Digital Innovation, Coca-Cola, and Vidya Nagarajan, a Senior Product Manager at Google, discussed how from store operations and ...
Sanjeev Sharma Joins November 11-13, 2018 @DevOpsSummit at @CloudEXPO New York Faculty. Sanjeev Sharma is an internationally known DevOps and Cloud Transformation thought leader, technology executive, and author. Sanjeev's industry experience includes tenures as CTO, Technical Sales leader, and Cloud Architect leader. As an IBM Distinguished Engineer, Sanjeev is recognized at the highest levels of IBM's core of technical leaders.
We are seeing a major migration of enterprises applications to the cloud. As cloud and business use of real time applications accelerate, legacy networks are no longer able to architecturally support cloud adoption and deliver the performance and security required by highly distributed enterprises. These outdated solutions have become more costly and complicated to implement, install, manage, and maintain.SD-WAN offers unlimited capabilities for accessing the benefits of the cloud and Internet. ...